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Endoproteolytic processing of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoproteins is an obligate part of the
biosynthetic pathway that generates functional, fusion-competent Env complexes, which are then incorporated into infectious virions. We
have examined the influence of cleavage on Env-specific antibody reactivity, Env incorporation into pseudovirions, and the infectivity and
neutralization sensitivity of Env-pseudotyped viruses. To do so, we have used both incompletely processed wild-type (Wt) Env and
engineered, cleavage-defective Env mutants. We find that there is no simple association between antibody reactivity to cell surface-expressed
Env, and the ability of the same antibody to neutralize virus pseudotyped with the same Env proteins. One explanation for the absence of such
an association is the diverse array of Env species present on the surface of transiently transfected cells. We also confirm that cleavage-
defective mutants are antigenically different from Wt Env. These findings have implications for the use of Env binding assays as predictors of
neutralizing activity, and for the development of cleavage-defective Env trimers for use as subunit immunogens.
D 2005 Elsevier Inc. All rights reserved.Keywords: gp160 Env; HIV-1; Cleavage; Antigenicity; Neutralizing antibodies; MutantsIntroduction
The human immunodeficiency virus type 1 (HIV-1)
envelope glycoprotein (Env) complex is initially synthe-
sized as a precursor protein, gp160, composed of the surface
glycoprotein, gp120, linked covalently to the transmem-
brane glycoprotein, gp41 (Gallo et al., 2003). The gp160
protein is trimerized during synthesis, via non-covalent
interactions between the gp41 subunits. Late in the synthetic
process gp160 is proteolytically cleaved by host cell
proteases, within the trans-Golgi network (TGN) or TGN-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.05.002
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E-mail address: jpm2003@med.cornell.edu (J.P. Moore).derived secretory vesicles, into its gp120 and gp41 subunits,
which remain non-covalently associated (Moulard and
Decroly, 2000). The receptor binding functions of Env are
located in the gp120 subunits, whereas the gp41 subunits
promote the fusion of the viral and cellular membranes after
receptor engagement (Berger et al., 1999; Gallo et al., 2003;
Poignard et al., 2001; Wyatt and Sodroski, 1998).
Virus-neutralizing antibodies (NAb) are directed against
the Env complex, which is therefore the basis of antibody-
based vaccines (Burton et al., 2004; Garber et al., 2004).
The first generation of Env vaccines involved monomeric
gp120 subunit proteins, or peptide fragments thereof
(Graham, 2002; McMichael and Hanke, 2003), but vaccines
of this type have been shown to be ineffective, or can05) 154 – 172
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al., 2005; Graham and Mascola, 2005). A common
approach to designing the next generation of Env-based
vaccines is to make oligomeric forms of Env (Chakrabarti et
al., 2002; Jeffs et al., 2004; Sanders et al., 2002; Srivastava
et al., 2002; Yang et al., 2000, 2002; Zhang et al., 2001).
The underlying assumption is that an Env protein that better
mimics the native, functional Env trimer present on virions
may be better able to stimulate the production of antibodies
reactive with that trimer, and hence capable of virus
neutralization (Burton et al., 2004).
The most common method of expressing oligomeric
forms of HIV-1 Env is to truncate gp41 immediately prior
to its transmembrane domain (Chakrabarti et al., 2002;
Jeffs et al., 2004; Sanders et al., 2002; Srivastava et al.,
2002; Yang et al., 2000, 2002; Zhang et al., 2001).
Oligomeric Env proteins are usually made by eliminating
the natural cleavage site between gp120 and gp41 via
mutation into a form that is not a substrate for cellular
proteases (Chakrabarti et al., 2002; Srivastava et al., 2002;
Yang et al., 2000, 2002; Zhang et al., 2001). But even if
the canonical cleavage site is unaltered, the efficiency of
cleavage is often low, causing uncleaved Env proteins to
be expressed as a minority, or even the dominant, species
(Jeffs et al., 2004; Srivastava et al., 2002; Staropoli et al.,
2000; Yang et al., 2000; Yuan et al., 2005). An alternative
way of making Env trimers is to ensure their efficient
cleavage while introducing additional, trimer-stabilizing
substitutions (Binley et al., 2000, 2002; Sanders et al.,
2002). It is not yet clear whether cleaved forms of the Env
trimer are superior immunogens compared to uncleaved
proteins, or whether any type of oligomer is substantially
better than monomeric gp120. There are, however,
mounting indications that Env oligomerization does allow
an incremental improvement in NAb induction in test
animals (Barnett et al., 2001; Bower et al., 2004; VanCott
et al., 1997; Yang et al., 2001).
Because of the continuing uncertainty about the optimal
way to induce NAbs using oligomeric forms of Env, we
have sought additional information on the impact that
cleavage has on the Env complex. To do so, we have
expressed cleaved and uncleaved forms of Env on the
surface of transfected cells, and studied their incorporation
into pseudoviruses and the properties of these viruses. Fully
infectious viruses generally contain only cleaved forms of
Env (Dubay et al., 1995), but this may not be true of
pseudoviruses. The latter are increasingly often used in
assays of HIV-1 neutralization (Binley et al., 2004;
Montefiori, 2004; Moore and Burton, 2004; Wei et al.,
2002; Yang et al., 2001), so we investigated whether the
extent of Env cleavage influences their sensitivity to NAbs.
Finally, a reliable assay of Env-antibody binding could
provide a simple surrogate of virus neutralization, but no
such assay presently exists because non-functional forms of
Env can bind antibodies and generate misleading signals
(Herrera et al., 2003; Poignard et al., 2003). We havecontinued to study whether antibody binding to uncleaved,
non-functional forms of Env contributes to this problem. In
these studies, we have used Env proteins from a neutraliza-
tion-sensitive virus, HXBc2, and its neutralization-resistant
derivative, 3.2P, that evolved in vivo during passage of
SHIV-HXBc2 in the rhesus macaque (Cayabyab et al.,
1999; Si et al., 2001).Results
Env expressed on the cell surface differs antigenically from
Env expressed on infectious virions
Multiple studies have revealed the lack of any simple
relationship between the binding of MAbs to Env proteins
expressed on the surface of Env-transfected cells and the
efficiency with which the same monodonal antibodies
(MAbs) neutralize the corresponding infectious viruses
(Herrera et al., 2003; Nichols et al., 2002; Sattentau and
Moore, 1995; Si et al., 2001; York et al., 2001). The
discrepancy is further illustrated when the binding of three
MAbs to cell surface expressed fusion competent (+) C-
terminally truncated gp140Dct Env proteins from the
HXBc2(+) and 3.2P(+) viruses after transient transfection
of 293T cells is compared with the abilities of the same
MAbs to inhibit the infectivity of pseudoviruses bearing
the same Env proteins and produced in the same 293T
cells (Fig. 1). HXBc2(+) is an env clone of the T-cell line-
adapted (TCLA) virus IIIB; 3.2P(+) is a neutralization-
resistant variant that arose upon passage of HXBc2(+) in a
rhesus macaque (Cayabyab et al., 1999; Si et al., 2001). In
preliminary experiments we found that full-length gp160
Env was poorly expressed at the cell surface. Hence, the
signal-to-noise ratio in flow cytometry-based assays was
inadequate for a meaningful, comparative analysis of the
binding of some test MAbs to various forms of Env (data
not shown). The C-terminally truncated (gp140Dct) Env
protein is expressed at higher levels because it lacks motifs
associated with gp41 down-regulation (Berlioz-Torrent et
al., 1999; Bultmann et al., 2001; Staropoli et al., 2000), so
we elected to study this form of Env instead (Herrera et
al., 2003). As test MAbs, we used b12 and 2G12, which
both have broad neutralizing activity, and 205-46-9, which
recognizes a CD4bs epitope and neutralizes TCLA but not
primary viruses efficiently (Burton et al., 1994; Fouts et
al., 1997; Trkola et al., 1996).
For both Env proteins, the rank order for the three MAbs
in the cell surface Env-binding assay was 2G12 > b12 >
205-46-9 (Figs. 1A and B). The maximal mean fluorescence
intensity (MFI) values were similar when the binding of all
three MAbs to the Env proteins from the neutralization-
sensitive HXBc2(+) virus was assessed (Fig. 1B). Further-
more, 2G12 and b12 bound with a higher maximal MFI to
the Env protein from the neutralization-resistant 3.2P(+)
virus than they did to HXBc2(+) Env, while the converse
Fig. 1. Binding of MAbs to Env on the surface of cells producing Env-pseudotyped viruses, and neutralization of the resulting pseudoviruses. HEK 293T cells
were co-transfected with plasmids encoding 3.2P(+) gp140Dct or HXBc2(+) gp140Dct Env, and ones encoding the CMV Pack gag-pol system, Luc, and
DsRed2. (A and B) The cells were labeled with different concentrations of MAb b12 (&), 2G12 (h), or 205-46-9 (r) followed by 10 Ag/ml of FITC-labeled
goat F(abV)2 anti-human IgG. Non-specific fluorescence due to the secondary antibody was subtracted when calculating MFI values. (C and D) The culture
supernatants containing Env-pseudotyped viruses bearing the 3.2P(+) gp140Dct or HXBc2(+) gp140Dct Env proteins were incubated for 1 h with the above
MAbs at the concentrations indicated prior to addition to U87.CD4.CXCR4 cells. Luciferase expression (RLU values) was determined after 4 days, then the
extent of neutralization by each input MAb was calculated. The percentage of neutralization was normalized relative to the RLU values obtained for cells
grown in the absence of virus (0% infectivity) and for cells infected with virus in the absence of MAb (100% infectivity).
C. Herrera et al. / Virology 338 (2005) 154–172156was seen with MAb 205-46-9 (although the difference was
small).
In the neutralization assay with the 3.2P(+) pseudovi-
rus, the rank order for the three MAbs was 2G12 = b12 >
205-46-9, with HXBc2 it was b12 > 2G12 > 205-46-9.
As expected, HXBc2(+) was more sensitive than 3.2P(+)
to b12 and 205-46-9, although 2G12 neutralized both
viruses with similar potencies (mean T SD 50% neutra-
lization concentrations for 3.2P(+), 0.26 T 0.13; for
HXBc2(+), 0.28 T 0.20 Ag/ml), which is consistent with
previous reports (Si et al., 2001, 2003). Thus, as outlined
below, 2G12 reactivity was sometimes used to normalize
the reactivity of the other test MAbs against different
forms of HXBc2 and 3.2P Env.
Overall, the results of the binding assay did not predict
the outcome of the neutralization assay, either qualita-
tively or quantitatively. Below, we investigate possible
reasons why the conformational state of Env proteins
might not be the same on mature virions as it is on the
cell surface prior to virion budding, because such differ-
ences could help explain the discrepant outcome of the
two assays.Quantification of Env cleavage fragments
The above results are broadly similar to ones we
described in an earlier study using Env proteins from
HIV-1 JR-FL. There, we raised concerns about the
interpretation of cell surface Env-binding assays, and
we also reported that Env proteins expressed on the
surface of transiently transfected cells were inefficiently
cleaved by cellular proteases (Herrera et al., 2003). Both
cleaved and uncleaved forms of Env can be present on
the cell surface, but only the fully cleaved Env
complexes on cells or virions mediate fusion and
infection (Dubay et al., 1995). It therefore seemed
possible that the heterogeneity of Env forms present on
the cell surface, particularly the mixture of cleaved and
uncleaved species, could account for the lack of any
relationship between the outcome of binding and neu-
tralization assays.
To study this issue further, we first had to identify a
suitable method to detect and quantify the cleaved and
uncleaved gp160 and gp140Dct proteins, and their
processed derivatives, gp120 and gp41. The simplest
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electrophoresis, then identify the different forms of Env
using specific MAbs. However, the efficiency with which
various Env species are detected by antibodies after
resolution on SDS-PAGE gels and transfer to a membrane
is likely to affect any estimate of the extent of Env
cleavage. To test this, we first incubated a sample of
purified, soluble monomeric JR-FL SOS gp140 (Binley et
al., 2000; Schulke et al., 2002) with increasing concen-
trations of DTT to separate it into gp120 and the gp41
ectodomain (gp41ECTO; mol. wt. ¨30–35 kDa), then
blotted the gel-resolved components using either MAb
2F5 (anti-gp41) or MAb B13 (anti-gp120). Consistent
with previous reports, the SOS gp140 protein was reducedFig. 2. Detection and semi-quantification of Env cleavage fragments. (A) Puri
concentrations indicated (nM) to separate the gp120 and gp41ECTO components
proteins were probed with the anti-gp120 MAb B13 or the anti-gp41 MAb 2F5
described in Materials and methods. Note that gp140 and gp120 proteins were de
The amount of input SOS gp140 protein (ng/lane) was varied in the presence of 100
293T cells transfected with gp140Dct versions of JR-FL, HXBc2(+), and 3.2P(+) E
used to probe the Western blot.to its components by DTT concentrations in the range
10–100 nM (Binley et al., 2000; Schulke et al., 2002).
However, although the B13 and 2F5 MAbs can both
recognize the cleaved (gp120 or gp41, respectively) and
uncleaved (gp140) Env forms, their use provided different
estimates of the extent of gp140 dissociation, because 2F5
detected gp41ECTO more sensitively than B13 detected
gp120 (Fig. 2A). The differential reactivity of the two
MAbs with the appropriate cleavage fragments therefore
causes some variation in estimates of SOS gp140
dissociation. With 2F5 detection, DTT-induced dissocia-
tion of SOS gp140 was estimated to be 81% (mean 80 T
7%; n = 12), but with B13 only 61% (mean 57 T 7%; n = 12)
(Fig. 2A). When the amount of input protein per gel lane wasfied monomeric JR-FL SOS gp140 (100 ng) was treated with the DTT
, then fractionated by SDS-PAGE. After transfer to a membrane, the Env
. The percentage cleavage of the SOS gp140 protein was determined as
tected by B13, while gp140 and gp41/gp41ECTO were detected by 2F5. (B)
mM DTT. (C) Biotinylated Env was avidin precipitated from the surface of
nv, co-transfected in the absence () or presence (+) of furin. MAb 2F5 was
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sensitively than gp120, in turn leading to a higher estimate
of cleavage when 2F5 was used as the detection antibody
(Fig. 2B).
Overall, we conclude that the most reliable and flexible
way to determine the extent of cleavage is to use 2F5 to
detect Env proteins resolved by SDS-PAGE. We cannot
exclude, however, the possibility that a systematic skew in
estimates of Env cleavage is caused by a differential
reactivity of 2F5 with gp160, gp140Dct, gp41, and
gp41ECTO proteins. There is no obvious way to address this
issue. Hence, when making estimates of Env cleavage,
relative values derived using similar Env proteins are likely
to be more reliable than absolute values obtained with
different ones.
Extent of cleavage of cell surface-expressed Env
We next sought to investigate the cleavage status of
Env proteins expressed on the surface of HEK 293T
cells. These cells are frequently used to make pseudovi-
rions for use in infectivity and neutralization assays.
Usually, these pseudovirions bear full-length Env pro-
teins, so it would be desirable also to study this form of
Env in biochemical and immunological assays. However,
as noted above, the C-terminally truncated gp140Dct Env
protein is expressed at higher levels than full-length
gp160. Hence, we chose to use the truncated gp140Dct
form for these assessments.
We found that the most sensitive and efficient method
for the detection and analysis of cell surface Env protein
cleavage fragments was to use the membrane-imperme-
able biotinylation reagent, Sulfo-NHS-LC-Biotin. The
biotin-labeled Env proteins were then precipitated with
avidin, fractionated by SDS-PAGE, then detected by
Western blotting with Env-specific MAbs. The unmodi-
fied JR-FL gp140Dct Env protein contains a functional
cleavage site, but despite this we found that it was
poorly (13%) cleaved. The extent of cleavage could be
improved by co-transfecting the endoprotease furin, but it
still did not exceed 50% (Fig. 2C). A variant of JR-FL
gp140Dct Env containing a hexa-arginine motif at the
cleavage site (R6-Env) (Binley et al., 2002) was cleaved
with 35% efficiency, but furin co-transfection still did not
increase the extent of cleavage of this protein beyond
¨50% (data not shown). The 3.2P(+) and HXBc2(+)
gp140Dct Env proteins were naturally better cleaved than
the corresponding JR-FL protein (¨50%, compared to
13%), but furin co-transfection had a negligible addi-
tional effect (<60% cleavage) (Fig. 2C). We conclude
that Env expressed at the surface of transiently trans-
fected 293T cells is poorly cleaved and that, while some
improvements are possible (e.g., by furin co-transfection
or the introduction of the R6-Env motif), a significant
fraction of Env (often >50%) remains in the uncleaved
form.The co-transfection of furin had no significant effect on
the binding of any of the test MAbs to Env expressed on
the surface of 293T cells (data not shown). Hence, either
too few additional Env protein complexes were cleaved to
make a significant difference to the overall antigenic
conformation of the cell surface Env population, or the
cleavage of individual Env complexes does not change
their configuration enough to affect their recognition by the
test MAbs.
Iodixanol purification of HIV-1 virions and pseudovirions
To study Env proteins on virions or pseudovirions, we
needed a method to purify the particles away from other
sources of Env. Standard purification methodology involves
ultracentrifugation, with or without a sucrose density
gradient, but can still contain a significant amount of
contaminating, cell-derived microvesicles (MV) (Bess et al.,
1997; Gluschankof et al., 1997). The presence of MV has
lead to overestimates of the amounts of several Fvirion-
associated_ proteins, in some cases necessitating re-analysis
of what truly is a virion component (Dettenhofer and Yu,
1999; Esser et al., 2001; Trubey et al., 2003). MV contain
Env but not Gag proteins (Bess et al., 1997; Trubey et al.,
2003). Uncleaved Env proteins have been reported to be
associated with MV at significant levels, as has gp41 which
is presumably indicative of the presence of cleaved Env
proteins (Adams and Scheid, 2001). Hence, MV-associated
Env proteins can potentially interfere with studies of the
Env content of virions or pseudovirions.
An alternative purification method uses iodixanol
(FOptiprep_), which has a lower osmolarity than sucrose
and has been reported to increase the resolution with which
different protein complexes can be separated at low
densities (Dettenhofer and Yu, 1999; Hammarstedt et al.,
2000; Sims et al., 2000; Tritel and Resh, 2000). We
therefore investigated whether iodixanol gradients could
improve the purification of virions and pseudovirions away
from contaminating MV.
Filtered preparations of pseudovirus derived from 293T
cells, or infectious virus derived from peripheral blood
mononuclear cells (PBMC), were centrifuged through a
20% sucrose cushion to remove soluble proteins, then
layered onto a 6–18% discontinuous iodixanol gradient
(Dettenhofer and Yu, 1999). After centrifugation, fractions
were removed from the top of the gradient and assayed for
their content of total protein (Coomassie blue) and viral p24
antigen (Dettenhofer and Yu, 1999). The virion-containing
fractions (judged by p24 antigen and infectivity assays)
were separated from the majority of total proteins added to
the iodixanol gradient (data not shown). Protein staining
methods are, however, unlikely to be sufficiently sensitive
for determining whether MV and virions are cleanly
resolved (Trubey et al., 2003). We therefore assessed the
extent of MV contamination of virion preparations by two
other methods.
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Env-pseudotyped virus into a PBMC-derived preparation of
MV (i.e., supernatant derived from uninfected PBMC).
After iodixanol gradient fractionation, the presence of MV
was identified by probing with an anti-CD45 MAb (Trubey
et al., 2003). CD45 is not expressed on 293T cells, so the
identification of this protein in a gradient fraction reflects
the presence of PBMC-derived MV. Pseudoviruses were
detected by probing the gradient fractions for p24 antigen
and by determining their infectivity (Fig. 3). The peak of
CD45 antigen was in fractions 9–12, whereas p24 antigen
and pseudoviruses were predominantly found in fractions
11–14. However, the MV peak was broad, and it over-
lapped significantly with the pseudovirus peak; even the
most enriched virion-containing fractions (12 and 13)
contained detectable amounts of CD45 (Fig. 3). A similar
finding was made using PBMC-grown fully infectious JR-
FL virus instead of 293T cell-derived pseudovirus (data not
shown).
In a second experiment, we transfected 293T cells with
3.2P(+) gp140Dct Env and luciferase plasmids in theFig. 3. Resolution of Env-pseudotyped viruses by iodixanol gradient. HIV-1 3.2P(+
cells and spiked into clarified supernatant from mitogen-activated PBMC prior to
pseudovirus infectivity using U87.CD4.CXCR4 cells (?) and for p24 antigen cont
Western blotting followed by probing with antibodies specific for CD45 (B) or pabsence of a Gag-expressing plasmid. No pseudoviruses
can form in these cells, although Env-containing MV
should be released. The cell-free supernatant was fractio-
nated on an iodixanol gradient in comparison with
authentic 293T cell-derived 3.2P(+) gp140Dct Env-pseu-
dotyped virus. The Gag-free fractions contained a
significant amount of particulate gp41/gp140Dct Env (as
detected with MAb 2F5), but of course no infectious
particles were present (data not shown). The fractions
containing the gp41/gp140Dct Env proteins overlapped
significantly with the p24-containing fractions from the
pseudovirion preparation. Again, this experiment suggests
that MV cannot be fully separated from pseudovirions,
even using iodixanol gradients.
In our general experience, the amount of Env present in
the peak iodixanol gradient fractions from Gag-free
supernatants (i.e., from 3.2P(+) gp140Dct Env/Luc plasmid
transfections) is usually less than that resolved in the same
fractions when Gag is present (i.e., including the CMV-
Pack expression vector) (Fig. 4A). Thus, we estimate that
MV-associated Env accounts for a significant (and) gp140Dct Env-pseudotyped viruses were derived by transfection of 293T
separation on a 6–18% iodixanol gradient. (A) Fractions were assessed for
ent (>). TCA-precipitated fractions were also analyzed by SDS–PAGE and
24 (C). The gel was stained with Coomassie blue (D).
Fig. 4. Env cleavage on pseudotyped viruses and the effect of furin. (A) AWestern blot of iodixanol-fractionated Env proteins derived from transfection of the
3.2P(+) gp140Dct Env plasmid, with or without plasmids encoding luciferase and the CMV Pack gag-pol system. Env and Gag bands were detected using the
2F5 and D7320 MAbs, respectively. (B) Env-pseudotyped viruses (3.2P(+) gp140Dct, JR-FL gp160, and HXBc2 gp160), expressed in the presence or
absence of exogenous Furin, were pelleted through a sucrose cushion then resolved by iodixanol gradient centrifugation. After TCA precipitation and Western
blotting, Env and Gag proteins were detected using the 2F5 MAb (anti-gp41) or the D7320 Ab (anti-p24). For comparison, PBMC-derived stocks of the
infectious viruses JR-FL and NL4/3 were analyzed using the same procedures. gp41160 and gp41140 are the gp41 moieties derived from gp160 and gp140,
respectively.
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or pseudovirion preparation. Whether the presence of this
contaminant Env will affect the outcome of various assays
cannot be stated with certainty, but the possibility should
always be taken into account. For simplicity, however, we
will continue to refer to the iodixanol gradient-fractionated
pseudovirus preparations as Fpseudovirus_, although they
contain a mixture of pseudovirions and MV.The extent of Env cleavage on gradient fractionated virions
and MV
Despite the issue of MV contamination, we still consid-
ered it worth examining the extent to which Env proteins
were cleaved on pseudovirus preparations. Env proteins were
cleaved to a similar extent on 293T cell-derived pseudovi-
rions bearing 3.2P(+) gp140Dct or JR-FL gp160 Env
C. Herrera et al. / Virology 338 (2005) 154–172 161proteins, average values being 70 T 6% (mean T SD, n = 5)
and 70 T 5% (n = 4), respectively. Co-transfection of furin
into the 293T cells increased the extent of cleavage of
pseudovirion-associated 3.2P(+) gp140Dct Env proteins to
86 T 7% (P < 0.05, Mann–Whitney U test). However, even
in the presence of furin, Env cleavage remained incomplete.
In a representative experiment, the JR-FL and HXBc2 gp160
proteins, and the 3.2P(+) gp140Dct protein, when expressed
in the context of Env-pseudotyped virus, were all cleaved to
similar extents (Fig. 4B).
The extent of Env cleavage on pseudovirions (70 T 6%,
n = 5, for 3.2P(+) gp140Dct) exceeds that seen when the
same Env protein is studied on the 293T cell surface (48 T
11%, n = 5; P < 0.01). Although this is a consistent finding,
the various influences on the precision of such estimates
prevent any definitive conclusion about whether cleaved
forms of Env are preferentially incorporated into virus
particles, as has been suggested by earlier studies (Dubay et
al., 1995; Iwatani et al., 2001; McCune et al., 1988).
Reducing the level of 3.2P(+) gp140Dct Env expression by
¨10-fold did not improve the level of cell- or pseudovirion-
associated Env cleavage (data not shown). Hence, incom-
plete cleavage may not be due simply to saturation of the
natural processing pathway in the TGN as a result of Env
over-expression after transfection.
Any conclusions about the configuration of Env on
pseudovirions would be substantially compromised if
uncleaved Env proteins were preferentially associated with
MV, but cleaved Env proteins were preferentially incorpo-
rated into pseudovirions. To test this, we generated MV by
co-transfection of 293T cells with 3.2P(+) gp140Dct Env
and Luc plasmids, and compared them with pseudoviruses
bearing the same Env. Env proteins were cleaved to similar
extents in MV and pseudovirion preparations, and furin co-
expression caused a similar increase in cleavage in both
cases (Fig. 4A, and data not shown). Hence, although
pseudovirus preparations are contaminated with MV, we
could find no evidence that their Env contents are
significantly different from one another, at least in respect
of their degree of cleavage.
The incomplete cleavage of Env on pseudovirions
detected with either the B13 (data not shown) or 2F5
MAbs contrasts with the almost complete cleavage seen
when PBMC-produced preparations of fully infectious
JR-FL and NL4/3 viruses were analyzed using the same
techniques (Fig. 4B, panel 4). It is possible that the
difference between viruses and pseudoviruses could be
due to variation in the amount of uncleaved Env proteins
present in contaminating MV released by the two cell
types, but we consider this unlikely. A more probable
explanation is that the difference is attributable to
producer cell-dependent effects (293T cells vs. PBMC)
to the method by which the env genes are introduced
into the producer cell (transfection vs. infection), or to
some other unknown factor relating to pseudovirion
production.Effect of Env cleavage on pseudovirion infectivity, MAb
recognition, and neutralization sensitivity
To assess the impact of Env cleavage on infectivity, we
titrated gradient-fractionated pseudovirions and measured
their infectivity-to-particle ratio (TCID50/ng p24). Thus,
typical infectivity-to-particle ratios, generated in the
absence of furin, were in the range of 103 to 104 TCID50
per ng p24 for 3.2P(+) gp140Dct, 102 to 104 for JR-FL.
Infectivity-to-particle ratios generated after furin co-trans-
fection were usually within 3-fold of the ratios obtained in
the absence of furin. The variation inherent to TCID50
determinations means that <3-fold differences in this ratio
could not be quantified accurately, whereas the propor-
tional increase in Env cleavage caused by furin co-
transfection usually does not exceed 30% (see Fig. 4).
Hence, while there is probably no substantial effect of
furin-induced Env cleavage on pseudovirus infectivity, a
minor influence would escape detection in this assay
system.
Antibody binding and neutralization assays are an
alternative, and perhaps superior, way to assess whether
increasing Env cleavage by furin co-transfection affects the
structure and function of pseudovirion-associated Env
proteins. We first studied the efficiency with which
sucrose-pelleted 3.2P(+) gp140Dct and HXBc2(+)
gp140Dct Env-pseudotyped virions could be captured onto
ELISA plate wells by four different gp120-specific reagents
(Fig. 5A). To normalize for variation in the amount of
virions captured, we calculated the ratio between the amount
of p24 antigen captured by each test agent and that captured
by MAb 2G12. The rationale for using MAb 2G12
reactivity in this way is essentially the same as that for the
flow cytometry studies of cell-surface-expressed Env, as
outlined above (Pancera and Wyatt, 2005; Si et al., 2001,
2003).
Furin co-transfection had no significant effect on the
extent of capture of either input virus by any of the test
reagents, CD4-IgG2, 205-46-9, or b12 (Fig. 5A). Hence,
either furin does not increase the extent of cleavage of
pseudovirion-associated Env significantly, or else the addi-
tional cleavage events do not detectably alter the reactivity
of Env with the test reagents. It is also notable that
neutralizing and non-neutralizing agents captured similar
amounts of neutralization-sensitive or -resistant pseudovi-
rions. For example, MAb 205-46-9 captured equivalent
amounts of 3.2P(+) and HXBc2(+) gp140Dct Env-pseudo-
typed virus, yet this MAb failed to neutralize 3.2P(+) Env-
pseudotyped virus (Figs. 5A and B). These observations add
to existing evidence on the limitations of virion-captured
ELISA methods for studies related to HIV-1 neutralization
(Poignard et al., 2003).
The co-expression of furin also had no significant
effect (P > 0.05; Mann–Whitney U test) on the
neutralization sensitivity of the iodixanol gradient-purified
pseudoviruses (Fig. 5B). As expected, the 3.2P(+)
Fig. 5. Furin co-transfection has no effect on the reactivity of pseudoviruses with Env-specific reagents, or on their neutralization sensitivity. (A) 3.2P(+)
gp140Dct or HXBc2(+) gp140Dct Env-expressing pseudoviruses were produced in cells in the presence (white bars) or absence (black bars) of co-transfected
furin, then purified on iodixanol gradients. The pseudoviruses were incubated with the plastic-immobilized reagents indicated, and the amount of immobilized
p24 antigen was measured. The ratio of the amount of p24 captured by each test reagent to that captured by MAb 2G12 is shown. (B) Pseudotyped viruses
bearing 3.2P(+) gp140Dct Env (?, >) or HXBc2(+) gp140Dct Env (h, g) were produced in the presence (open symbols) or absence (closed symbols) of co-
transfected furin. They were incubated for 1 h at 37 -C with 2G12, CD4-IgG2, 205-46-9, or b12 at the concentrations indicated, prior to addition to
U87.CD4.CXCR4 cells. The outcome of infection (luciferase expression in RLU) was determined after 4 days and the percentage of neutralization by each test
reagent was calculated.
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resistant compared to their HXBc2(+) gp140Dct counter-
parts (Cayabyab et al., 1999; Si et al., 2001). Similar
results were obtained using pseudoviruses bearing JR-FL
gp160 Env (data not shown).
These experiments suggest that the uncleaved, but
nevertheless cleavage-competent, Env proteins associated
with pseudovirion preparations have little or no impact on
biologically relevant events such as virus–cell fusion and its
inhibition by NAbs.Effect of cleavage site disruption on Env surface expression,
processing, sialylation, and incorporation into
pseudovirions
The above studies were all performed using cleavage-
competent Env proteins that were imperfectly processed by
cellular proteases during synthesis. A more drastic way to
modify the extent of Env cleavage is to eliminate the
primary cleavage site (at residues 508–511) by mutagenesis
to make cleavage-defective Env proteins (Adams and
C. Herrera et al. / Virology 338 (2005) 154–172 163Scheid, 2001; Dubay et al., 1995; Si et al., 2003; Srivastava
et al., 2002; Yang et al., 2002). The cleavage-defective Env
proteins were expressed on the surface of transfected 293T
cells and compared to the cleavage-competent forms that
retained a scissile cleavage site (although this is used
inefficiently, as shown above). Biotinylation and Western
blotting procedures were used to confirm that disruption of
the cleavage site did indeed reduce the appearance of the
gp41 cleavage product. However, despite the introduction of
this cleavage-disrupting motif, the levels of apparent
cleavage (as judged by detection of gp41 and the uncleaved
gp140Dct) were comparable to those obtained for cleavage-
competent, wild-type (Wt) JR-FL gp140Dct Env (Fig. 6A,
lanes 1 and 2). Similarly, the 3.2P() gp140Dct cleavage-
defective Env (SEKS mutant) was still cleaved to a
significant level (mean T SD, 34 T 19%; n = 5) by
comparison with Wt cleavage-competent 3.2P(+) gp140Dct
Env (48 T 11%; n = 5) (Fig. 6B). Similar results were
obtained with the IEGR cleavage-defective mutant of
3.2P() gp140Dct Env (data not shown).
One likely explanation is that an upstream cleavage site
(KAKRRV, residues 500–505), unaffected by the above
substitutions, is being used at low efficiency (Dubay et al.,
1995). When the primary and secondary cleavage sites were
both disrupted by the introduction of a hexameric Leu-Arg
(LR6) motif (Binley et al., 2000), no cleavage was
detectable. Thus, no gp41 could be identified on the cell
surface (Fig. 6A, lane 3, and data not shown). Low-level
cleavage of supposedly uncleavable Env proteins is another
factor to take into account when analyzing Env protein
configurations.
Disrupting the cleavage site by mutagenesis can result in
a highly sialylated, high molecular weight Env band in
addition to the 140 or 160 kDa band that corresponds to the
naturally uncleaved Env protein (Adams and Scheid, 2001;
Freed et al., 1989; McCune et al., 1988; Pancera and Wyatt,
2005). We too detected a high molecular weight band when
we analyzed cell surface expressed 3.2P() gp140Dct Env
proteins. This band was desialylated when the cells were
first treated with neuraminidase (Fig. 6B, inset). Similar
results were obtained in experiments using HxBc2
gp140Dct, HXBc2 gp160, and JR-FL gp160, suggesting
that the phenomenon is a general one (Fig. 6A, and data not
shown). The highly sialylated forms of cleavage-knockout
Env proteins can appear as a smearing of the gp140 band,
rather than as a distinct band (Fig. 6A, and data not shown).
Hence, multiple, different partially sialylated Env moieties
are probably produced, rather than the single dominant Env
form that is seen when, e.g., the 3.2P() gp140Dct Env
protein is expressed. The reason for such a difference
remains unclear, although the observation has been made
consistently (Adams and Scheid, 2001; Freed et al., 1989;
McCune et al., 1988). However, Western blotting revealed
that this high molecular weight band was not associated
with iodixanol gradient-enriched Env-pseudotyped virus
bearing the 3.2P() gp140Dct Env and no shift in theestimated size of the uncleaved Env protein occurred when
such preparations were treated with neuraminidase (data not
shown). These observations suggest that the high molecular
weight, highly sialylated forms are specifically excluded
when Env proteins are incorporated into nascent virions.
To assess whether sialylated and lower molecular weight
forms of Env differ antigenically, we treated 3.2P()
gp140Dct Env-transfected 293T cells with neuraminidase
then stained them with an anti-Env MAb (2G12, b12, 205-
46-9, or 2F5). As a control for the efficiency of neurami-
nidase treatment, we used wheat germ agglutinin (WGA), a
lectin that binds to N-acetylglucosamine and N-acetylneur-
aminic acid (sialic acid) residues. Desialylation of either the
cleavage-competent or cleavage-defective forms of Env did
not alter their reactivity with any of the anti-Env MAbs.
However, the binding of WGA to cells expressing the
cleavage-defective Env proteins was decreased by neurami-
nidase, confirming that the enzyme had successfully
removed sialic acid residues (data not shown). Hence,
either the sialylated forms of Env are present in amounts too
low to influence the overall reactivity of cell surface Env
with MAbs, or the sialic acid residues do not significantly
modify the epitopes for the test MAbs.
We next sought to determine whether cleavage-compe-
tent or cleavage-defective forms of Env were recognized
differently by neutralizing and non-neutralizing MAbs (Fig.
6C, and data not shown). 2G12 binding was again used to
normalize for variation in the expression of the different Env
proteins on the surface of transfected 293T cells (Si et al.,
2001, 2003). Each of the b12, 2F5, and 205-46-9 MAbs
reacted poorly with the cleavage-competent form of Env
from the neutralization-resistant 3.2P strain, compared to the
cleavage-defective form of the same Env. The higher level
of MAb reactivity, as a function of 2G12 binding, with the
cleavage-defective 3.2P() gp140Dct Env protein was
comparable to that observed using either the cleavage-
competent or the cleavage-defective forms of Env from the
neutralization-sensitive HXBc2 strain. Thus, for Env from
the neutralization-resistant 3.2P strain, the presence of an
intact cleavage site, even one that is incompletely utilized, is
associated with an Env configuration that is less efficiently
recognized by MAbs. This conclusion does not, however,
apply to Env from the neutralization-sensitive HXBc2
strain. Thus, consistent with our previous report (Si et al.,
2003), the conformations of cleavage-competent Env
proteins are subtly different from those of cleavage-
defective proteins when each form is expressed on the
surface of transiently transfected cells.
The amount of Env protein associated with density-
fractionated pseudovirion preparations was similar for both
Wt and cleavage-defective forms. However, the infectivity
of pseudovirions containing cleavage-defective Env was
profoundly impaired; the decrease in the infectivity-to-
particle ratio compared to Wt was 100- to 1000-fold. Thus,
the mean TCID50 per ng p24 (TSD, n = 4) for 3.2P(+)
gp140Dct was 1080 T 1499, but for 3.2P() gp140Dct it
Fig. 6. The consequences of disrupting the Env cleavage site by mutagenesis. (A) Cleavage-competent Wt JR-FL gp140Dct and the cleavage-defective JR-
FL() and (/) gp140Dct proteins were expressed on the surface of transiently transfected 293T cells. After biotinylation and avidin precipitation, Env was
detected with MAb 2F5. (B) 293T cells expressing cleavage-competent and cleavage-defective forms of 3.2P gp140Dct Env were biotinylated and lysed. The
extracts were avidin precipitated, gel resolved, and blotted with MAb 2F5. Inset: the effect of treatment of the cells with 200 mU/ml of neuraminidase (NA)
prior to surface biotinylation. (C) The reactivity of MAbs with Env on the surface of transfected 293T cells was measured by flow cytometry. Cleavage-
competent 3.2P(+) gp140Dct Env (black bars); cleavage-competent HXBc2(+) gp140Dct Env (shaded bars); cleavage-defective 3.2P() gp140Dct Env (gray
bars); cleavage-defective HXBc2() gp140Dct Env (open bars). The binding of each MAb is shown as the ratio to the binding of 2G12 to the same Env. (D)
Pseudoviruses derived from 293T cells expressing the cleavage-competent (solid bars) or cleavage-defective (open bars) forms of 3.2P Env were purified by
centrifugation through a 20% sucrose cushion. The particles were then assayed for infectious virus content (right panel) and the presence of particulate Env (left
panel) using a virus capture ELISA based on MAb 2G12. A goat anti-human IgG Fc-specific Ab was used as negative control.
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however, confer a residual, low level of infectivity, yielding
luciferase values 0.1–3.5% as high as those for the Wt
3.2P(+) gp140Dct Env. This limited degree of infectivity
may be attributable to the residual cleavage of Env that still
occurs despite the supposedly inactivating substitutions at
the primary cleavage site (see Figs. 6A and B). Either
cleavage still occurs with low efficiency at the mutated
primary site, or else the upstream secondary cleavage site is
used instead, with the resulting gp120-gp41 complex
functioning at a low level. An alternative explanation is
that pseudovirions may be able to infect target cells by a
mechanism other than Env-mediated fusion, albeit very
inefficiently.
As noted above, contaminating MV and their associated
Env content can interfere with assessments of pseudovirus
Env. This concern also applies to the present studies of
cleavage-defective Env proteins. However, although MV
do contain Env proteins, they lack Gag (Bess et al., 1997;
Trubey et al., 2003). We therefore performed a capture
ELISA to test whether particles captured by the anti-Env
MAb 2G12 also contained Gag, and whether the amount of
captured Gag varied with the form of Env present on the
particles. When gradient-purified pseudovirions bearing
either the Wt 3.2P(+) or cleavage-defective form of 3.2P
gp140Dct Env were tested in this way, similar amounts of
p24 were captured in both cases (Fig. 6D, left panel).
Hence, both Wt and cleavage-defective Env proteins had
been successfully incorporated into Gag-containing, pseu-
dovirus particles. However, only the pseudovirions bearing
Wt Env were infectious when U87.CD4.CXCR4 cells
indicator cells were added to the MAb-captured particles
(Fig. 6D, right panel).
Taken together, these results demonstrate that non-
functional, cleavage-defective Env forms can be expressed
at the cell surface and be incorporated into pseudovirion
particles, but they react differently with MAbs when
compared with Wt Env.Discussion
We have continued to investigate the impact that the
cleavage of Env proteins has on their structure and function.
The first reason for this study is that uncleaved forms of
Env, usually made by deliberately eliminating the cleavage
site between gp120 and gp41, are now being evaluated as
vaccine antigens (Chakrabarti et al., 2002; Srivastava et al.,
2002; Yang et al., 2000, 2002; Zhang et al., 2001). It is
presently unknown whether the lack of cleavage makes this
form of Env a better or a worse immunogen than other Env
configurations. But there are indications that cleaved and
uncleaved Env proteins do differ in their exposure of
epitopes for neutralizing and non-neutralizing antibodies, so
it does seem relevant to explore these differences (Pancera
and Wyatt, 2005; Schulke et al., 2002; Si et al., 2003). Asecond reason is that binding assays intended to study the
properties of anti-Env antibodies, commonly use Env
proteins expressed on the surface of transfected cells (Fouts
et al., 1997; Gorse et al., 2004; Herrera et al., 2003; Lee et
al., 2002; Nichols et al., 2002; Park et al., 2000; Si et al.,
2001; York et al., 2001). We and others have shown that a
significant proportion of total cell surface Env proteins is in
the uncleaved form (Abrahamyan et al., 2005; Dubay et al.,
1995; Herrera et al., 2003; Moulard et al., 1999; Pancera and
Wyatt, 2005; Si et al., 2003; York et al., 2001). Furthermore,
for this or other reasons, there is no simple correlation
between the binding of antibodies to cell surface Env and
their ability to neutralize viruses expressing the same or
related Env proteins (Abrahamyan et al., 2005; Herrera et
al., 2003; Moulard et al., 1999; Pancera and Wyatt, 2005; Si
et al., 2003; York et al., 2001). The final reason was because
neutralization assays using pseudoviruses are now becom-
ing very widely used as analytical tools (Binley et al., 2004;
Moore and Burton, 2004; Richman et al., 2003; Wei et al.,
2002; Yang et al., 2001; Zhang et al., 2004). Pseudoviruses
are made by transfection, usually of 293T cells. As Env
proteins expressed on these cells are predominantly
uncleaved, it seemed worthwhile investigating whether this
also applied to the proteins incorporated into pseudovirions
and, if so, whether this influenced the outcome of
neutralization assays.
Env configurations on the cell surface
Our investigations of antibody binding to cell surface
Env reinforce the conclusion that any correlation between
the outcome of binding and neutralization assays is, at best,
limited (Herrera et al., 2003; Nichols et al., 2002; Pancera
and Wyatt, 2005). And anomalies abound. We investigated
several possible explanations for why Env-binding and virus
neutralization assays yield discrepant results; any or all of
them might contribute to the overall problem.
We confirmed that most of the cleavage-competent Env
proteins expressed on transiently transfected cells are not
cleaved (Dubay et al., 1995; York et al., 2001). Cleaved and
uncleaved (i.e., cleavage-defective) proteins are antigeni-
cally different (Pancera and Wyatt, 2005; Si et al., 2003).
This is probably one factor contributing to the above
discrepancy. Thus, the uncleaved proteins are not functional
and the binding of Abs to these proteins is irrelevant to the
outcome of neutralization or fusion-inhibition assays. Some
Env changes that supposedly eliminate the primary cleavage
site still allow scission to occur at detectable levels, possibly
through a secondary cleavage site a few residues upstream
of the primary cleavage site. Moreover, we found that
cleavage-defective Env proteins are differentially sialylated
compared to cleavage-competent forms (Adams and Scheid,
2001; Freed et al., 1989; McCune et al., 1988; Pancera and
Wyatt, 2005). Presumably, the cleavage-defective proteins
are processed by a pathway that is not the same as the one
followed by the natural Env proteins, leading to their
C. Herrera et al. / Virology 338 (2005) 154–172166exposure to a different array of cellular glycan-modifying
enzymes at one or more stages of their migration through
the endoplasmic reticulum and Golgi apparatus. This again
suggests that the cleavage-defective and cleavage-compe-
tent forms of Env must be structurally different, at least to
an extent. The potential for the generation of irrelevant
readouts in binding assays therefore seems obvious,
particularly when multiple antigenic forms of Env are
present.
The cell surface Env binding assays were all performed
in the presence of co-expressed Gag proteins, and Gag
proteins are obviously also present in pseudovirions.
However, we used Env proteins that were truncated within
the intracytoplasmic region of gp41, close to the membrane-
spanning domain. These gp140Dct forms of Env therefore
lack the C-terminal regions of gp41 that interact with the
p17 matrix protein (Rao et al., 1995). Gag-Env interactions
can influence Env conformation (Freed and Martin, 1996;
Murakami et al., 2004; Wyma et al., 2004), the maturation
of Gag proteins subsequent to virion budding may trigger
further conformational changes in Env (Murakami et al.,
2004), and the presence of Gag proteins can modify the
clustering of full-length Env proteins on the cell surface
(Hermida-Matsumoto and Resh, 2000). Hence, it is possible
that additional influences might be brought to bear on the
Env structures on fully infectious viruses that do not apply
to pseudoviruses, or to Env-binding assays that also use
gp140Dct Env proteins (Abrahamyan et al., 2005; Edwards
et al., 2002; Freed and Martin, 1996; Murakami et al., 2004;
Wyma et al., 2004). The use of the truncated Env proteins is
often necessary because full-length gp160 is usually
expressed at too low a level to be satisfactorily detected in
flow cytometry-based binding assays, probably due to its
high rate of down-regulation (Berlioz-Torrent et al., 1999;
Bultmann et al., 2001; Staropoli et al., 2000; Yuste et al.,
2004). This may be yet one more reason why studies on C-
terminally truncated forms of Env on the surface of
transfected cells do not correlate with the outcome of
neutralization assays using fully infectious viruses.
Overall then, several factors probably contribute to the
presence of multiple forms of Env on the surface of
transfected cells and the differences between these proteins
and those present on naturally infectious virus particles. The
variables include Env cleavage, or the lack of it; hyper-
sialylation; the truncation of the intracytoplasmic domain of
gp41; and the presence or absence of Gag proteins able to
interact with full-length gp41. Taken together, it is perhaps
not surprising that cell surface Env-binding assays generate
signals that are hard to reconcile with the outcome of
neutralization assays using fully infectious viruses, or even
ones using pseudoviruses that bear the same, C-terminally
truncated Env proteins. Furthermore, the extent to which
uncleaved Env is expressed at the cell surface, and then
incorporated into viruses or pseudoviruses, is likely to be
influenced by the cell type, the level of Env expression in
that cell, and by the Env sequence that is used. Reinforcingthe latter point, differences between the processing of wild-
type and cleavage-defective forms of JR-FL and YU2 Env
proteins have been described (Pancera and Wyatt, 2005).
Great caution must therefore be applied when interpreting
binding assays of this type (Fouts et al., 1997; Gorse et al.,
2004; Herrera et al., 2003; Lee et al., 2002; Nichols et al.,
2002; Park et al., 2000; Si et al., 2001). Overall, we strongly
recommend that they not be used to judge the outcome of
vaccine trials or to study the properties of neutralizing or
non-neutralizing antibodies.
Env configurations on pseudoviruses
It seemed reasonable to examine whether Env-pseudo-
typed virions contain a significant proportion of uncleaved
Env proteins. The effectiveness of virion purification
methodologies is controversial, since both HIV-1-infected
and vector-transfected cells release MV which co-sediment
with infectious virions during sucrose gradient centrifuga-
tion. We used iodixanol as the gradient medium, as it is
reported to allow better resolution of protein complexes at
lower densities (Dettenhofer and Yu, 1999; Mouland et al.,
2000; Tritel and Resh, 2000). However, the effectiveness of
even iodixanol gradient fractionation has recently been
questioned (Trubey et al., 2003). Our own results using
CD45 immunoblotting to detect MV do confirm that
iodixanol-fractionated virus preparations are still MV-con-
taminated. Moreover, some Env proteins are present in MV
derived from 293T cells. The presence of other sources of
particulate Env therefore influences the interpretation of
studies intended to study the properties and quantities of
Env proteins on pseudovirions. Caution is therefore
appropriate. For example, estimates on the incorporation
of Env and other viral or non-viral proteins into pseudovi-
rions may be affected by the probable presence of co-
sedimenting MV (Dettenhofer and Yu, 1999; Esser et al.,
2001; Trubey et al., 2003). Also, the presence of aberrant
forms of Env and/or co-sedimenting MV-associated cellular
proteins could lead to unwanted immune responses in
immunization studies using virus-like particles.
Because of MV contamination, we could not make a
definitive determination as to whether pseudovirions gen-
erated by transient transfection, particularly of 293T cells,
do or do not incorporate uncleaved Env proteins. However,
several circumstantial lines of evidence, when taken
together, do suggest that significant amounts of uncleaved
Env are present on pseudovirus particles. Firstly, both
soluble and membrane-bound Env proteins are incompletely
cleaved when transiently expressed at high levels, meaning
that uncleaved proteins can certainly be exported from the
cell (Abrahamyan et al., 2005; Binley et al., 2000; Dubay et
al., 1995; Herrera et al., 2003; Jeffs et al., 2004; Moulard et
al., 1999; Si et al., 2003; Staropoli et al., 2000). Secondly,
immobilized anti-Env MAbs capture similar levels of Gag
protein from pseudovirus preparations bearing either cleav-
age-defective or cleavage-competent Env proteins. Thirdly,
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approximately the same as that found in preparations
containing both pseudovirions and MV, and co-expression
of furin had a similar effect on cleavage in both cases.
Finally, in on-going studies we have found that the co-
expression of cleavage-defective and cleavage-competent
Env proteins leads to dominant-negative inhibition of
pseudovirus infectivity. The dominant-negative effect is
likely to be attributable to interactions between the different
forms of Env on the surface of pseudovirions (Beddows,
Herrera, Moore and Klasse, unpublished results).
There are, however, several reports suggesting that
uncleaved Env proteins are preferentially excluded from
budding virus and pseudoviruses particles (Dubay et al.,
1995; Iwatani et al., 2001; McCune et al., 1988). If an
exclusion mechanism does exist, it must yet again imply
that uncleaved and cleaved forms of Env are structurally
distinctive, as both forms are certainly present on the cell
surface. We also noted that highly sialylated forms of Env
proteins appear to be excluded from pseudoviruses, again
suggesting the existence of some form of quality control
mechanism at the stage of Env incorporation. Uncleaved
Env proteins were incorporated into Env-pseudotyped
virions in amounts readily detectable by their reactivity
with both anti-gp120 and anti-gp41 MAbs. Although
uncleaved proteins constituted only a minority of the total
Env content of the pseudoviruses, their presence contrasts
with the consistent observation that fully infectious, CD4+ T
cell-derived virus preparations seemingly incorporate only
cleaved forms of Env (Cordelier et al., 2003; Murakami and
Freed, 2000; Trubey et al., 2003). Hence, the nature of the
producer cell could be a significant variable that affects the
Env content of HIV-1 particles. Another source of variation
is the extent of Env expression. Transient transfection could
cause the expression of more Env proteins than the cell can
process successfully, allowing leakage of uncleaved forms
into pseudoviruses whether or not there exists an active
exclusion mechanism. The level of Env cleavage could be
improved slightly by furin co-expression, suggesting that
the natural enzymes can indeed become substrate saturated.
But even in the presence of furin, uncleaved Env proteins
were still associated with pseudovirion preparations. Taken
together, our observations suggest that pseudovirions con-
tain significant amounts of uncleaved Env proteins, whereas
PBMC-derived infectious viruses probably contain a much
lesser amount.
The uncleaved Env content of pseudoviruses does not
appear to compromise their performance in virus neutrali-
zation assays, because only functional, fully cleaved Env
proteins are involved in virus infectivity and its neutraliza-
tion. However, the presence of a low level of defective Env
forms, which are preferentially recognized by non-neutral-
izing antibodies, could skew any measurement of the
interactions between antibodies and virions. For example,
virions could incorporate defective Env forms such as
uncleaved, misfolded, and/or differentially glycosylated Envas well as Env spikes that have shed some or all of their
gp120. Consequently, virus-capture assays are as flawed as
cell surface Env binding assays; both methods generate
misleading information about the relationship between Env
binding and virus neutralization (Cavacini and Posner,
2004; Cavacini et al., 2002; Nyambi et al., 1998, 2000;
Poignard et al., 2003). In neither case can it be assumed that
when a MAb binds to an Env protein, it is necessarily
interacting with a functional trimer capable of involvement
in the fusion or infection process (Parren et al., 1998).Conclusions
We have addressed several consequences of Env
processing in vitro that relate to the development of
candidate subunit, or whole virion, vaccines based on
cleavage-defective Env. We have also investigated the value
of Env binding assays as a surrogate for neutralization
assays, as well as the use of Env-pseudotyped viruses for
studying HIV-1 neutralization. Our studies show that the use
of Env-pseudotyped viruses does not appear to be compro-
mised by the presence of improperly processed Env proteins
on the pseudovirion surface. However, transiently trans-
fected cells should not be used to measure antibody binding
to cell surface Env because the presence of multiple forms
of Env on the cell surface severely degrades the value of any
resulting information. The different ways in which cleavage-
defective Env and Wt forms of Env are processed, and their
differing antigenic profiles, may be relevant to under-
standing the outcome of immunization studies involving
uncleaved Env proteins. To date, uncleaved gp140 oligo-
mers appear to be a little superior to monomeric gp120
proteins in their ability to induce NAbs (Barnett et al., 2001;
Bower et al., 2004; Grundner et al., 2005; VanCott et al.,
1997; Yang et al., 2001), but not yet to an extent that is
likely to provide a robust answer to the ‘‘neutralizing
antibody question’’ that presently bedevils HIV-1 vaccine
research (Burton et al., 2004). Whether cleavage, or the lack
of it, has a significant influence on Env immunogenicity and
whether cleaved forms of Env oligomers might offer
improvements remain to be determined.Materials and methods
Reagents and plasmids
Human MAb 205-46-9 was obtained from Michael Fung
(Tanox Inc, Houston, TX) and previously designated HT7
(Fouts et al., 1997). MAb b12 was a gift from Dennis
Burton (Scripps Research Institute, La Jolla, CA; Burton et
al., 1994). MAbs 2F5 and 2G12 were provided by Herman
Katinger (Polymun Scientific Inc, Vienna, Austria) (Muster
et al., 1993; Trkola et al., 1996). The CD4-IgG2 molecule
(PRO 542) and purified monomeric gp140 SOS were gifts
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al., 1995). HIVIG was obtained from the New York Blood
Center (Nichols et al., 2002). MAb B13 (Chessie 13) was
provided by the AIDS Research and Reference Reagent
Program, NIAID, NIH, contributed by George Lewis.
Antibody D7320 is an anti-p24 sheep polyclonal antibody
(Cliniqa Corp., Fallbrook, CA).
Env genes encoding full-length gp160 proteins from
HIV-1 JR-FL and HXBc2 were cloned using PCR from
source (Trkola et al., 1998) templates into the mammalian
expression vector pCI (Promega, Madison, WI). Cleavage
site mutants of the gp140Dct version of JR-FL, gp140Twt
(Herrera et al., 2003), were generated using site-directed
mutagenesis (Stratagene, La Jolla, CA). The JR-
FL()gp140Dct mutant was made by altering the primary
cleavage site, residues 508–511 of the gp120 C5 domain,
REKR to IEGR (R508I/K510G). In the JR-FL(/)Dct
mutant, the KRRVVQREKRAV furin recognition sequence
was replaced with a hexameric Leu-Arg motif, LRLR-
LRLRLRLR (Binley et al., 2000). The pNL4/3.Luc plasmid
(also known as pNL-Luc-ER+) was obtained from
Nathaniel Landau (Connor et al., 1996).
The neutralization-resistant variant 3.2P of the HXBc2
virus has been described previously (Cayabyab et al., 1999),
as have the functional Wt 3.2P(+) and HXBc2(+) gp140
(Dct) Env clones (Si et al., 2001). The 3.2P() and
HXBc2() variants of these Env proteins have the primary
cleavage site between gp120 and gp41 altered to SEKS to
prevent cleavage by furin-family endoproteases (Si et al.,
2003). An alternative modification to the primary cleavage
site, identical to that introduced into JR-FL Env (REKR to
IEGR), was made by site-directed mutagenesis. When both
primary cleavage site mutants, SEKS and IEGR, were
compared directly, we could find no significant qualitative
differences between them; we therefore refer to them both as
cleavage-defective Env(). Recombinant reporter viruses
expressing 3.2P or HXBc2 gp140 Env were generated by
co-transfection with env plasmid, packaging plasmid
(pCMVDP1DenvpA referred to here as CMV Pack), and
an HIV-1 vector plasmid expressing firefly luciferase (pLuc)
as described (Si et al., 2001).
The plasmid pcDNA3.1-Furin, expressing the cellular
endoprotease furin, has been described elsewhere (Binley et
al., 2000). The pDsRed2-N1 plasmid, expressing DsRed2,
was obtained from Clontech (Palo Alto, CA).
Cell lines and conditions for transfections
All cell cultures were maintained at 37 -C in an
atmosphere containing 5% CO2. Human embryonic
kidney (HEK) 293T cells were grown in Dulbecco’s
minimal essential medium (GIBCO, Grand Island, NY)
containing 10% fetal calf serum, 2 mM l-glutamine,
antibiotics (100 U/ml penicillin, 100 Ag/ml streptomycin),
and 0.5 mg/ml of the neomycin analog G-418.
U87.CD4.CCR5 and U87.CD4.CXCR4 cells (providedby Dan Littman) were cultured in the same conditions
described for HEK 293T cells but with 0.3 mg/ml of G-
418 and 0.5 Ag/ml of puromycin. PBMC were isolated
from healthy HIV-seronegative donors by Ficoll-Hypaque
centrifugation, mitogen stimulated as previously described
(Gordon et al., 1999), and maintained in RPMI 1640
medium containing 10% FBS, 2 mM l-glutamine, anti-
biotics (100 U of penicillin/ml, 100 Ag of streptomycin/
ml), and 100 U of interleukin—2/ml.
HEK 293T cells were transiently transfected following
the calcium phosphate precipitation method (Profection
mammalian transfection system-calcium phosphate; Prom-
ega). Briefly, plasmids were co-transfected into HEK 293T
cells in a 6-well plate containing 3 ml of culture medium
without antibiotics. The cells were washed 15 h later and re-
fed with 3 ml of the same culture medium.
Detection and biotinylation of surface Env
The expression and cleavage of Env proteins on the
surface of transiently transfected cells was assessed by
biotinylation with the membrane-impermeable reagent,
EZ-link Sulfo-NHS-LC-Biotin, according to the manufac-
turer’s instructions (Pierce Biotechnology, Rockford, IL).
Following incubation with this reagent for 45 min at 4 -C,
the cells were washed extensively and lysed in TSA buffer
(10 mM Tris (pH 8), 150 mM NaCl) containing 1%
Nonidet-P40 (NP40), 1 mM phenylmethylsulfonyl fluoride
(PMSF), and 1 ‘‘Complete Cocktail Protease Inhibitors’’
(Roche Diagnostic GmbH, Mannheim, Germany). The
supernatant solutions were clarified by centrifugation and a
portion was kept aside to represent the Ftotal cell lysate_
fraction. The remainder was mixed with Avidin–agarose
(Pierce Biotechnology) to precipitate biotin-labeled pro-
teins. The pellets were washed in TSA containing a
decreasing (1–0.01%) amount of NP40, then boiled in the
presence of polyacrylamide gel electrophoresis (PAGE)
loading buffer supplemented with 2% sodium dodecyl
sulfate (SDS) and 100 mM dithiothreitol (DTT). The
solubilized proteins were resolved on a reduced SDS-
PAGE gradient (8–16%) Tris–glycine gel (Invitrogen,
Carlsbad, CA), and transferred to a PVDF membrane prior
to immunoblotting.
Purification of HIV-1 by iodixanol gradient centrifugation
Pseudoviruses were generated by transient transfection of
293T cells, then enriched by velocity gradient centrifugation
on 6–18% iodixanol gradients (Optiprep; Axis-Shield,
Oslo, Norway) essentially as described elsewhere (Det-
tenhofer and Yu, 1999). In some experiments, the furin
protease was co-transfected into the 293T cells. Infectious
HIV-1 stocks generated in PBMC were processed in the
same way. Briefly, virion-containing supernatants were
clarified by low speed centrifugation, filtered through a
0.45-Am membrane, then pelleted through a 20% sucrose
C. Herrera et al. / Virology 338 (2005) 154–172 169cushion for 1.5 h at approximately 100,000  g in an
SW41Ti rotor (Beckman Coulter, Inc, Miami, FL). The
virion-containing pellet was resuspended in phosphate-
buffered saline (PBS), layered onto an iodixanol gradient
(6–18% iodixanol in PBS, in 1-ml volume with 1.2%
increments), then centrifuged at approximately 250,000 
g for 1.5 h in an SW41Ti rotor. Sequential fractions were
taken from the top of the gradient and assayed for virion
protein (p24 antigen) content by ELISA, as previously
described (Trkola et al., 1995) and for infectivity (lucifer-
ase quantitation of cell lysates, Promega) using
U87.CD4.CCR5 or U87.CD4.CXCR4 cells as appropriate.
Briefly, 50 Al of each gradient fraction was added to
microplate wells in which U87.CD4.CCR5 or U87.
CD4.CXCR4 cells had been seeded at 3  103 cells/well
24 h earlier. After incubation for 4 days, the cells were
washed with PBS and lysed with 100 Al of luciferase cell
culture lysis reagent (Binley et al., 1997). Fifty microliters
was transferred to a white, opaque assay plate for luciferase
quantification in a Dynex MLX luminoter (Chantily, VA),
using 50 Al of luciferase assay reagent. The extent of
luciferase expression was recorded in relative light units
(r.l.u). In some cases, the reverse transcriptase content of
the same fractions was also determined using a reverse
transcriptase chemiluminescence assay (Roche Diagnos-
tics). Material remaining from each gradient fraction was
stored at 80 -C for subsequent analysis. The integrity of
the formed gradients was always confirmed by weighing
comparably processed gradient preparations on an analyt-
ical balance. For Western blot analyses, gradient-derived
samples were precipitated on ice with 8–10% trichloro-
acetic acid, washed in ice-cold acetone, then resuspended
in 1 PAGE loading buffer. The solubilized proteins were
analyzed by SDS-reduced PAGE followed by Coomassie
staining or immunoblotting, as described above. The extent
of Env cleavage was estimated by determining the propor-
tionate area under the curve for resolved forms of Env
proteins, using the National Institutes of Health Image
software (version 1.63). The extent of Env cleavage is
defined by the amount of the cleavage fragment (gp41 or
gp120) detected as a proportion of the total resolved Env
proteins.
Infectivity and neutralization assays
To estimate the infectivity of pseudovirus preparations,
U87.CD4.CCR5 or U87.CD4.CXCR4 cells were infected
with pseudovirion-containing supernatants and luciferase
expression was quantified after 3–4 days as described
above. The 50% tissue culture infectious dose (TCID50)
value was determined by the Spearman–Karber method.
Neutralization assays were performed using a stand-
ardized amount of pseudovirion-containing culture super-
natants normalized for infectivity. Pseudoviruses were
mixed with serially diluted MAb for 1 h at 37 -C, then
added to U87.CD4.CCR5 or U87.CD4.CXCR4 cells. Theluciferase content of cell lysates was measured 3–4 days
post-infection, as described above.
When iodixanol gradient-purified pseudovirions were
analyzed, the fraction containing the peak amount of
infectious material was identified by luciferase and p24
antigen assays. The resulting TCID50/ng p24 value provided
a basis for comparison with other pseudovirus or virus
preparations. Neutralization assays were performed using a
pool of the 3–4 fractions of gradient-purified pseudovirus
preparations that contained the highest levels of infectious
material. The TCID50 value of a sample of the same pool
was also determined to allow retrospective confirmation that
the amounts of infectious pseudovirus present in different
preparations were comparable.
Virus capture ELISA
Virus capture assays were performed as described by
Poignard et al. (2003). Briefly, 96-well ELISA plates
(Corning Inc., Corning, NY) coated with 5 Ag/ml of goat
anti-human IgG Fc-specific Ab (Sigma, St. Louis, MO)
were washed twice with ELISAwash buffer (EWB) (25 mM
Tris–HCl pH 8.0, 150 mM NaCl–0.05% Tween 20). After
blocking for 90 min at room temperature (RT) with 100 Al
of 5% bovine serum albumin in PBS, the plates were
washed twice with EWB and incubated with anti-gp120 or
anti-gp41 MAb (10 Ag/ml in 50 Al of PBS) for 2 h at RT.
The plates were then washed 10 times with EWB, thrice
with PBS, and incubated for 4 h at RT with 50 Al of
pseudotyped virus that had been concentrated through a
sucrose cushion as described above and resuspended in
DMEM containing 10% FBS. After 10 washes with PBS,
half of the wells were treated with 75 Al of lysis buffer
containing 0.5% Triton X-100 for p24 quantification. The
remaining wells were processed for quantification of the
infectivity of captured pseudoviruses. This was achieved by
incubation with 200 Al of U87.CD4.CXCR4 cells (5  103/
well) for 3 days followed by a luciferase assay, as described
above.
Immunostaining assay
Transfected HEK 293T cells (2  106 per sample) were
harvested, washed with PBS, and incubated for 1 h at room
temperature with 50 Al of a solution containing a test MAb.
The cells were then washed with cold PBS and fixed in 2%
paraformaldehyde, 60 mM sucrose in PBS, pH 7.4, for 15
min at room temperature. After two washes with PBS
containing 20 mM glycine (buffer A), the cells were
incubated for 15 min at room temperature with buffer A
containing 1% BSA and 0.05% NaN3 (buffer B). Samples
were stained with 10 Ag/ml goat F(abV)2 anti-human IgG-
FITC (Biosource, Int., Camarillo, CA) in buffer B (45 min
at room temperature), washed three times, and re-suspended
in the same buffer for flow cytometry analysis. Stained cell
suspensions were analyzed using an Epics Elite flow
C. Herrera et al. / Virology 338 (2005) 154–172170cytometer (Coulter Corporation, Hialeah, FL). FITC and
DsRed2 excitations were achieved by the use of a 488-nm
Argon laser lamp, and the fluorescence emissions were
collected using 525 nm and 575 nm band-pass filters,
respectively. The parameters used to select cell populations
for analysis were forward and side light-scatter, followed by
double-positive fluorescence. A total of 8000 events within
the double-positive population was collected for analysis
(Herrera et al., 2003).
Neuraminidase treatment
HEK 293T cells (1  106) were incubated with 200 mU/
ml of neuraminidase (sialidase from Clostridium perfrin-
gens; Roche Diagnostic) for 1 h at 37 -C and washed with
PBS before analysis.Acknowledgments
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